Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
This study has been terminated.
Study NCT00040170   Information provided by Transgene
First Received: June 21, 2002   Last Updated: October 31, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostatic Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
MVA-MUC1-IL2
Additional drug interventions recognized in this trial
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Antineoplastic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Transgene
University of California, Los Angeles
The Cleveland Clinic
University of Arizona


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services